PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.
-0.26
Negative OCF/share while AGEN has 10.60. Joel Greenblatt would question the viability of operations in comparison.
-0.26
Negative FCF/share while AGEN stands at 8.79. Joel Greenblatt would demand structural changes or cost cuts.
-1.22%
Negative ratio while AGEN is 17.04%. Joel Greenblatt would question whether the firm’s OCF is negative or capex is abnormally large.
0.87
1.25–1.5x AGEN's 0.74. Bruce Berkowitz would investigate if the competitor’s accruals hide weaker conversions.
-2398.28%
Negative ratio while AGEN is 51.94%. Joel Greenblatt would see if the company’s revenues or cash flows are fundamentally flawed.